Posey, Jennifer E.
O’Donnell-Luria, Anne H.
Chong, Jessica X.
Harel, Tamar
Jhangiani, Shalini N.
Coban Akdemir, Zeynep H.
Buyske, Steven
Pehlivan, Davut
Carvalho, Claudia M.B.
Baxter, Samantha
Sobreira, Nara
Liu, Pengfei
Wu, Nan
Rosenfeld, Jill A.
Kumar, Sushant
Avramopoulos, Dimitri
White, Janson J.
Doheny, Kimberly F.
Witmer, P. Dane
Boehm, Corinne
Sutton, V. Reid
Muzny, Donna M.
Boerwinkle, Eric
Günel, Murat
Nickerson, Deborah A.
Mane, Shrikant
MacArthur, Daniel G.
Gibbs, Richard A.
Hamosh, Ada
Lifton, Richard P.
Matise, Tara C.
Rehm, Heidi L.
Gerstein, Mark
Bamshad, Michael J.
Valle, David
Lupski, James R.
Article History
Received: 12 June 2018
Accepted: 5 December 2018
First Online: 18 January 2019
Disclosure
: Baylor College of Medicine (BCM) and Miraca Holdings Inc. have formed a joint venture with shared ownership and governance of Baylor Genetics (BG), formerly the Baylor Miraca Genetics Laboratories (BMGL), which performs clinical exome sequencing and chromosomal microarray analysis for genome-wide detection of CNV. J.R.L. serves on the Scientific Advisory Board of BG. J.R.L. has stock ownership in 23andMe, is a paid consultant for Regeneron Pharmaceuticals, and is a coinventor on multiple United States and European patents related to molecular diagnostics for inherited neuropathies, eye diseases and bacterial genomic fingerprinting. The other authors declare no conflicts of interest.